BARCELONA, Spain--(BUSINESS WIRE)--Oct 19, 2025--

Faeth Therapeutics today announced results from the international DICE trial, a randomized phase 2 study of sapanisertib (TAK228) plus weekly paclitaxel versus paclitaxel alone in women with platinum-resistant or recurrent epithelial ovarian or fallopian tube cancer. The trial was selected for a Late-Breaking Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2025 and met its pre-ordained statistical design and there is sufficient evidence of a positive signal to justify a larger phase 3 design.

134 patients were enrolled across sites in the UK and Germany. Median age was 62 years and nearly half had received three or more prior therapies. The combination achieved mean progression-free survival (PFS) of 5.8 mon

See Full Page